Comparative Pharmacology
Head-to-head clinical analysis: DUAC versus FINACEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAC versus FINACEA.
DUAC vs FINACEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUAC (clindamycin 1% / benzoyl peroxide 5%) combines clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, a keratolytic and antimicrobial agent that releases free radical oxygen, reducing Propionibacterium acnes and comedones.
Azelaic acid inhibits microbial protein synthesis, reduces reactive oxygen species production, and modulates keratinocyte and melanocyte function.
Clindamycin 1% / benzoyl peroxide 5% gel: apply a thin film to affected areas twice daily (morning and evening).
Apply a pea-sized amount topically twice daily (morning and evening) to affected areas of the face.
None Documented
None Documented
Terminal elimination half-life of clindamycin is 2.4 hours in adults with normal renal function; prolonged to 3.7-5.1 hours in hepatic impairment; clinical context: dosing interval may need adjustment in severe hepatic disease.
Not determined clinically due to negligible systemic absorption; after topical application, plasma levels are below quantification limits; no terminal half-life is established.
Renal excretion of unchanged clindamycin (10%) and metabolites; biliary/fecal excretion of inactive metabolites; approximately 90% of dose recovered in urine and feces over 6 days.
Renal: primarily as unchanged drug (minimal metabolism); approximately 16% of a topical dose is absorbed and excreted renally; fecal excretion is negligible.
Category C
Category C
Topical Acne Agent
Topical Acne Agent / Rosacea Treatment